AstraZeneca PLC (AZN.ST)
Stay on top of your portfolio with a custom homepage and newsletter. Start today!
Stock Price Variations Over Last 10 Days
ENHERTU (fam-trastuzumab deruxtecan-nxki) Achieved a Tumor Response Rate of 45.3% in Patients With HER2-Positive Metastatic Colorectal Cancer in Phase II DESTINY-CRC01
Jun 1, 2020